QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=79EFB6511D5206F7AAFBBEE69BF4889D;jsessionid=CFAF814A7400BB600DFFC7DE7E3AEA0C;jsessionid=4FD93B366FF19236AB405E0ABDAB6B30;jsessionid=BA28D091720EE6ED29812F09A5FB1853;jsessionid=8577B92025A6F5F849208DDD9AC4B6F3;jsessionid=0A9D7805B0C8EA4798ECB5A7C676C9EC (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=79EFB6511D5206F7AAFBBEE69BF4889D;jsessionid=CFAF814A7400BB600DFFC7DE7E3AEA0C;jsessionid=4FD93B366FF19236AB405E0ABDAB6B30;jsessionid=BA28D091720EE6ED29812F09A5FB1853;jsessionid=8577B92025A6F5F849208DDD9AC4B6F3;jsessionid=0A9D7805B0C8EA4798ECB5A7C676C9EC